OneSkin has secured US$20m Series A investment from growth equity firm Prelude Growth Partners to accelerate its position in the longevity beauty space.
The cash injection will be used to supercharge the biotech skin care brand’s next chapter of growth, underscoring the “long-term potential” of skin longevity as a category.
OneSkin was founded in 2016 by four Brazilian scientists, using longevity science to extend skinspan – the period skin remains healthy and functional – using the brand’s peptide OS-01.
The peptide prevents the accumulation of senescent cells, which are ageing cells that accumulate over time, contributing to inflammation and collagen breakdown.
“We are incredibly proud to welcome Prelude Growth Partners to the OneSkin family,” said Carolina Reis Oliveira, co-founder and CEO of OneSkin.
“Their team’s expertise in building modern consumer brands and their enthusiasm for our science-driven approach made this a natural fit.
“We were not looking for new capital — but their passion and belief in our vision made this an opportunity to expand our resources and work alongside people we deeply admire.
“We got ourselves a dream team.”
The investment is a “significant milestone” for the brand as it was not actively seeking new capital at the time.
Prelude Growth Partners approached the brand with a desire to invest, and OneSkin leveraged the opportunity to replace an early seed stage investor with a partner “who could best support them” in this next stage of growth.
“OneSkin’s cutting-edge science, novel proprietary technology, leadership in skin longevity and compelling brand are truly unique in the category,” said Alicia Sontag, co-founder and Managing Partner of Prelude Growth Partners.
“We are extremely proud to have the opportunity to partner with Carolina, Alessandra and the team at OneSkin to support them in creating an iconic, powerhouse brand of the future.”
OneSkin’s bestselling products include OS-01 Face, Body and Eye and OS-01 Lip and Hair, garnering celebrity fans such as actress Jennifer Aniston and singer Katy Perry.
The company closed another Series A investment round back in November 2024, led by Selva Ventures, alongside Unilever Ventures, Plus Capital and Able Partners.
Additional investors include Brazilian-American model and designer Camila Alves McConaughey, the spouse of Oscar-winning actor Matthew McConaughey.
American television personality Martha Stewart has also entered the longevity skin care arena with new range Elm Biosciences, while L’Oréal is also investing heavily in the science.
The French beauty giant plans to take longevity beauty mainstream, with new skin care and devices that focus on a “new era of better ageing”.
L’Oréal-owned brand Lancôme is the first out of the door with an offering, which includes a rose-derived PDRN-inspired product and a new diagnostic device which can educate consumers on their skin’s biological age.